Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry

Affiliation:	1. Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, the Netherlands;2. Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Chemical Biology & Drug Development, Universiteitsweg 99, 3584 CG Utrecht, the Netherlands;3. The Netherlands Cancer Institute, Division of Pharmacology, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands;4. The Netherlands Cancer Institute, Department of Pharmacy & Pharmacology, Louwesweg 6, 1066 EC Amsterdam, the Netherlands;1. Department of Pathology, Foundation Medicine, Inc., Cambridge;2. Department of Pathology, Albany Medical Center, Albany, USA;3. Center for Precision Medicine, Zhejiang University International Hospital, Hangzhou, China;4. Department of Pathology, University of Colorado School of Medicine, Aurora;5. Department of Medical Oncology, Thomas Jefferson University, Philadelphia;6. Medical Oncology, Moffitt Cancer Center, Tampa;7. Clinical Development;8. Clinical Genomics, Foundation Medicine, Inc., Cambridge;9. Division of Medical Oncology, University of Colorado School of Medicine, Aurora, USA;1. Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States;2. Department of Medicine, Massachusetts General Hospital, Boston, MA, United States;3. Departments of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States;4. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Abstract:	Small molecule inhibitors such as Larotrectinib have been recently approved in the treatment of patients with fusions of the neurotrophic-tropomyosin receptor tyrosine kinase (NTRK) genes 1-3. These genomic rearrangements have been reported across different tumor subtypes with a high prevalence in rare tumors. However, in gastric and esophageal adenocarcinoma (AGE) NTRK fusions have also been described in a subset of Asian patients. In order to study the prevalence of this alteration in Caucasian patients with AGE we performed immunohistochemistry for pan-NTRK in 438 formalin-fixed paraffin embedded (FFPE) tumor samples. While we found NTRK expression in gastric glands and tumor adjacent nerve tissue, we did not detect this marker in the tumor compartment. Based on our findings NTRK fusions do not seem to play a role in the molecularpathology of Caucasian AEG patients, so that other treatment options are required.

Keywords:	Neurotrophic-tropomyosin receptor tyrosine kinase (NTRK) gene fusion Gastric and esophageal adenocarcinoma (AGE) Larotrectinib
本文献已被 ScienceDirect 等数据库收录！

设为首页 | 免责声明 | 关于勤云 | 加入收藏